Show us a sign: The search for "game changing" prostate cancer biomarkers

The Lancet Oncology

Volumn 12, Issue 3, 2011, Pages 204-206

  Quinn, David ^a   Gross, Mitchell ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANDROGEN; CISPLATIN; CYTOTOXIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; HISTONE; KI 67 ANTIGEN; PROSTATE SPECIFIC ANTIGEN; TAXANE DERIVATIVE; TUMOR MARKER;

ADJUVANT THERAPY; ANALYTIC METHOD; BREAST CANCER; CANCER GROWTH; CANCER RECURRENCE; CANCER RESISTANCE; CANCER STAGING; CELL CYCLE PROGRESSION GENE; DNA REPAIR; GENE; GENETIC SCREENING; HISTOPATHOLOGY; HUMAN; LETTER; LUNG CANCER; LUNG RESECTION; MEDICAL TECHNOLOGY; METASTASIS; ONCOGENE K RAS; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROSTATECTOMY;

BIOLOGICAL MARKERS; HUMANS; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 79952037835     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(11)70003-1     Document Type: Letter

References (9)

1. Quinn DI, Henshall SM, Sutherland RL Molecular markers of prostate cancer outcome. Eur J Cancer 2005, 41:4623-4632.
2. Olaussen KA, Dunant A, Fouret P, et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 2006, 355:983-991.
3. Dahabreh IJ, Terasawa T, Castaldi PJ, Trikalinos TA Systematic review: anti-epidermal growth factor receptor treatment effect modification by KRAS mutations in advanced colorectal cancer. Ann Intern Med 2011, 154:37-49.
4. Marchionni L, Wilson RF, Wolff AC, et al. Systematic review: gene expression profiling assays in early-stage breast cancer. Ann Intern Med 2008, 148:358-369.
5. Cuzick J, Swanson GP, Fisher G, et al. Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study. Lancet Oncol 2011, published online Feb 9. 10.1016/S1470-2045(10)70295-3.
6. Seligson DB, Horvath S, Shi T, et al. Global histone modification patterns predict risk of prostate cancer recurrence. Nature 2005, 435:1262-1266.
7. Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010, 363:411-422. for the IMPACT Study Investigators.
8. de Bono JS, Logothetis CJ, Fizazi K, et al. Abiraterone acetate (AA) plus low dose prednisone (P) improves overall survival (OS) in patients with metastatic castration resistant prostate cancer (MCRPC) who have progressed after docetaxel-based chemotherapy (Chemo): results of COU-AA-301, a randomized double-blind placebo-controlled phase III study. Ann Oncol 2010, 21(suppl 8):LBA5.
9. de Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 2010, 376:1147-1154. for the TROPIC Investigators.